Cargando…

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure

BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockenstein, Edward, Ubhi, Kiren, Trejo, Margarita, Mante, Michael, Patrick, Christina, Adame, Anthony, Novak, Philipp, Jech, Marion, Doppler, Edith, Moessler, Herbert, Masliah, Eliezer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122761/ https://www.ncbi.nlm.nih.gov/pubmed/25047000 http://dx.doi.org/10.1186/1471-2202-15-90

Ejemplares similares

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick’s Disease and Fronto-Temporal Tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
por: Masliah, Eliezer, et al.
Publicado: (2011)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
por: Valera, Elvira, et al.
Publicado: (2015)

Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke
por: Bajenaru, O, et al.
Publicado: (2010)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
por: Muresanu, Dafin F., et al.
Publicado: (2016)

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
por: Guekht, Alla, et al.
Publicado: (2017)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases
por: Alvarez, X. Anton, et al.
Publicado: (2016)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity
por: Price, Diana L., et al.
Publicado: (2010)

APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
por: Crews, Leslie, et al.
Publicado: (2009)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
por: Overk, Cassia R, et al.
Publicado: (2014)

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
por: Bender, Andreas, et al.
Publicado: (2013)

Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha‐synuclein in oligodendrocytes
por: Tank, Jens, et al.
Publicado: (2014)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity
por: Fields, Jerel A., et al.
Publicado: (2016)

Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer
por: Fields, Jerel, et al.
Publicado: (2013)

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
por: Xu, Jiqing, et al.
Publicado: (2016)

Differential Effects of UCHL1 Modulation on Alpha-Synuclein in PD-Like Models of Alpha-Synucleinopathy
por: Cartier, Anna E., et al.
Publicado: (2012)

Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice
por: Spencer, Brian, et al.
Publicado: (2008)

S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease
por: Sunico, Carmen R, et al.
Publicado: (2013)

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease
por: Alvarez, X Anton, et al.
Publicado: (2020)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
por: Kim, Changyoun, et al.
Publicado: (2018)

Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery
por: Jianu, DC, et al.
Publicado: (2010)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
por: Mandler, Markus, et al.
Publicado: (2015)

Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders
por: Crews, Leslie, et al.
Publicado: (2011)

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease
por: Desplats, Paula, et al.
Publicado: (2012)

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021)

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial
por: Gharagozli, K, et al.
Publicado: (2017)

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u5udua447j78u8aug9e6p5sd8q